Mehta also is appointed as member of the Board of Directors.
AB Wire
Khush Mehta has been appointed President, Chief Executive Officer, and a member of the Board of Directors of CardioDx Inc., a molecular diagnostics company specializing in cardiovascular genomics, based in Redwood City, California.
As CEO, Mehta succeeds David Levison, who has been named the Chief Strategy Officer of the company, according to a press release.
Prior to joining CardioDx, Mehta served as the Global Head of the Healthcare Enterprise Solutions at Siemens. He has also held additional executive leadership roles at Siemens Healthcare, including Chief Strategy Officer and Head of Siemens Healthcare Asia Pacific. He earned a Bachelor and a Master of Commerce and Economics at the Sydenham College of Commerce and Economics in Mumbai, India along with a Master of Business Administration in competitive strategies and international finance from Yale University.
“This is an exciting time of change within healthcare. Khush is a proven leader with a track record for execution, clear business vision, and a demonstrated record for driving growth and profitability for companies,” said Ajit Singh, Chairman of the Board, in a statement. “With his extensive years of leadership experience, Khush has a deep understanding of the global healthcare marketplace and its supply chain, and possesses strong operational acumen to drive commercial success in the U.S. and international markets. Having worked with Khush previously, I know that his skills will accelerate the next phase of expanded growth and innovation.”
“I am honored and excited to lead CardioDx in advancing the commercialization of the Corus CAD test during this transformational time within the healthcare industry,” said Mehta, in a statement. “The Promise trial substudy recently presented at the 65th American College of Cardiology Annual Scientific Meeting further underscored the science behind our test that gives physicians an effective solution for clinical decision-making for obstructive coronary artery disease.1 I look forward to working with the entire CardioDx team as we embark on this journey for improving the quality of cardiovascular care.”